Heart failure & cardiomyopathiesTrial design
Vasodilation, loop diuretics, or their combination in acute heart failure: Rationale and design of the randomized placebo-controlled DECONGEST-AHF trial
- pragmatic, multicenter, randomized, double-blinded, placebo-controlled trial
- rationale and design
- 5 Danish hospitals
- emergency consent procedures
Study context
- Population
- Patients with suspected acute heart failure included no later than 3 hours after emergency department arrival, with acute dyspnea, clinical signs of congestion, oxygen saturation <94% or need for oxygen therapy, and systolic blood pressure ≥100 mmHgplanned enrollment
- Participants
- 1,041 patients
- Planned comparison
- intravenous furosemide, intravenous isosorbide dinitrate, or both as initial in-hospital treatment
- Primary endpoint
- days alive and outside of the hospital
- Follow-up
- 30 days
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Vasodilation, loop diuretics, or their combination in acute heart failure: Rationale and design of the randomized placebo-controlled DECONGEST-AHF trial. Am Heart J. Published 25 April 2026. doi:10.1016/j.ahj.2026.107461
Summarised from the published abstract; every number is checked against it